Galera Therapeutics receives Nasdaq delisting notice for failure to meet $50M MVLS requirement

Galera Therapeutics, Inc.

Received Nasdaq notice on June 8, 2022 for non-compliance with minimum Market Value of Listed Securities of $50M.
Has 180 days, until December 5, 2022, to regain compliance by closing at $50M+ for 10 consecutive business days.
Stock continues trading on Nasdaq Global Market under symbol GRTX; may consider transfer to Nasdaq Capital Market.
No assurance of regaining compliance; failure may lead to delisting subject to appeal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.